Ascendis Pharma A/S
Investors that purchased the Company’s securities and have suffered a loss, please fill in transaction information below, or email to info@portnoylaw.com.
There is no cost or obligation associated with submitting your information. If you are a shareholder who suffered a loss, please submit your contact information and purchase information to participate in the putative class action.
We also encourage you to contact Lesley F. Portnoy of The Portnoy Law Firm, at 310.692.8883, to discuss your rights free of charge. You can also reach us through the firm’s website at www.portnoylaw.com, or by email at info@portnoylaw.com.
If you choose to take no action, you can remain an absent class member.
Joining the case through the Portnoy Law website enables investors to learn about their legal claims and take an active role in recovering their losses.
The Portnoy Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
CONTACT:
Portnoy Law Firm
Lesley F. Portnoy, Esq.,
www.portnoylaw.com
Office: 310.692.8883
1800 Century Park East, Suite 600
Los Angeles, CA 90067
info@portnoylaw.com
The investigation is focused on determining whether or not the Company provided investors with false or misleading statements or failed to disclose pertinent information. On April 3, 2023, Ascendis revealed to the market that the U.S. Food & Drug Administration (FDA) had notified them of deficiencies in their New Drug Application (NDA) for TransCon PTH (palopegteriparatide) in hypoparathyroidism, which prevented the FDA from further discussing labeling and post-marketing requirements/commitments. The company did not previously disclose these deficiencies in the letter. Following this announcement, Ascendis’ shares dropped by 31% during intraday trading.
